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Background—Diminished aortic flow may induce adverse downstream vascular and renal signals. Investigations in a heart
failure animal model have shown that continuous aortic flow augmentation (CAFA) achieves hemodynamic
improvement and ventricular unloading, which suggests a novel therapeutic approach to patients with heart failure
exacerbation that is inadequately responsive to medical therapy.
Methods and Results—We studied 24 patients (12 in Europe and 12 in the United States) with heart failure exacerbation
and persistent hemodynamic derangement despite intravenous diuretic and inotropic and/or vasodilator treatment.
CAFA (meanSD 1.340.12 L/min) was achieved through percutaneous (n19) or surgical (n5) insertion of the
Cancion system, which consists of inflow and outflow cannulas and a magnetically levitated and driven centrifugal
pump. Hemodynamic improvement was observed within 1 hour. Systemic vascular resistance decreased from
1413453 to 1136381 dyne · s · cm5 at 72 hours (P0.0008). Pulmonary capillary wedge pressure decreased from
28.54.9 to 19.87.0 mm Hg (P0.0001), and cardiac index (excluding augmented aortic flow) increased from
1.970.44 to 2.270.43 L · min1 · m2 (P0.0013). Serum creatinine trended downward during treatment (overall
P0.095). There were 8 complications during treatment, 7 of which were self-limited. Hemodynamics remained
improved 24 hours after CAFA discontinuation.
Conclusions—In patients with heart failure and persistent hemodynamic derangement despite intravenous inotropic and/or
vasodilator therapy, CAFA improved hemodynamics, with a reduction in serum creatinine. CAFA represents a
promising, novel mode of treatment for patients who are inadequately responsive to medical therapy. The clinical impact
of the observed hemodynamic improvement is currently being explored in a prospective, randomized, controlled trial.
(Circulation. 2005;112:3107-3114.)
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The prevalence of heart failure among Americans is nearly5 million, with more than 500 000 newly diagnosed
cases each year.1 There are approximately 1 million annual
US hospitalizations with the primary diagnosis of heart
failure, with an estimated 44% of discharged patients read-
mitted within 6 months.1,2 Although medical therapy for
chronic heart failure has advanced substantially, improve-
ments in the treatment of decompensated heart failure have
lagged behind.3
Various types of mechanical circulatory support devices
are approved for clinical practice, as a bridge to cardiac
transplantation or as destination therapy.4,5 Although selec-
tion of the type of device is based on type of heart failure, size
of the patient, and experience of the institution, the main
objective is to functionally supplement or replace flow from
the failing ventricles in patients with decompensated heart
failure. The placement of these devices, which pump blood
from the left ventricle (LV) into the aorta, requires major
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surgical expertise in specialized centers. A less invasive
device, which can produce sustained hemodynamic and
clinical improvement, would be desirable to fill this gap in
treatment.
Investigations in a chronic, microembolic, ischemic heart
failure canine model have demonstrated that institution of
continuous aortic flow augmentation (CAFA), using the
Cancion system (Orqis Medical Corporation), results in
reduction in left heart filling pressure and volumes and
augmented LV ejection fraction (EF).6 On the basis of the
hypothesis that reduced aortic flow results in adverse down-
stream vascular and renal signals, this novel system com-
prises a miniature extracorporeal pump that augments aortic
flow continuously throughout the cardiac cycle. It does not
require any mechanical connection to the heart. A previous
report demonstrated hemodynamic and clinical improvement
with this system in a single patient with severe, decompen-
sated heart failure.7 The observed salutary effects have been
consistent with progressive vasodilation, ventricular unload-
ing, and augmented renal perfusion.
We now report results from the first 24 patients undergoing
CAFA with the Cancion system, who constitute the combined
enrollment within feasibility trials performed in the United
States and in Europe. Patients enrolled manifested acute
exacerbation of chronic heart failure with hemodynamic
derangement, which was uncorrected with intravenous diuret-
ic and inotrope and/or vasodilator therapy. We report results




Patients were enrolled under 2 investigational protocols, one in
Europe and one in the United States, with similar entry and exclusion
criteria. Protocols were approved, respectively, by individual center
ethics committees (Europe; 9 sites) and investigational review boards
(United States; 4 sites). All patients gave written, informed consent.
Entry criteria included the following: age 18 to 80 years; hospital-
ization owing to acute exacerbation of chronic heart failure mani-
festing increasing dyspnea and/or fatigue and/or exercise intolerance;
need for hemodynamic monitoring, based on clinical judgment;
treatment with intravenous diuretics and inotropic and/or vasodilator
therapy, with either clinical response judged to be inadequate or
recurrence of signs and symptoms on weaning attempt; elevated
pulmonary capillary wedge pressure (PCWP; Europe: 20 mm Hg;
United States: 18 mm Hg); stable drug doses (Europe: 2 hours;
United States: 6 hours); reduced LVEF (Europe: 35%; United
States:25%); and abnormal renal function or high diuretic require-
ment (serum creatinine 1.5 mg%, estimated creatinine clearance
60 mL/min,8,9 or intravenous furosemide dose 120 mg over 24
hours). Exclusion criteria included systolic blood pressure
80 mm Hg or clinical cardiogenic shock; recent Q-wave myocar-
dial infarction (30 days) or cardiac surgery (Europe: 7 days;
United States: 30 days); concomitant use of other forms of
mechanical support; cerebral vascular accident or transient ischemic
attack within the prior year; severe renal impairment (Europe: on
dialysis; United States: on dialysis or serum creatinine 3.0 mg%);
history of ventricular fibrillation or sustained ventricular tachycardia,
in the absence of correctable cause, unless an implantable cardiac
defibrillator was present; clinically significant peripheral vascular
disease; coagulopathy or inability to receive heparin; evidence of
systemic infection; and other life-threatening or debilitating disease.
Description of the Device
In animal models of heart failure, we have found that superimposing
additional continuous flow onto pulsatile aortic flow within the
descending aorta results in ventricular unloading and improved
hemodynamics. The Cancion system consists of a pump, tubing, and
arterial access cannulas and is designed to recirculate blood from the
iliac artery to the descending thoracic aorta in a continuous,
nonpulsatile manner (Figure 1). Inflow to the pump is achieved with
a 15-cm-long, 12F cannula percutaneously inserted via the left
femoral artery. In the first 5 patients, outflow from the pump was via
a 27-cm-long PVC/expanded PTFE graft cannula (6-mm expanded
PTFE graft section) anastomosed to the left axillary artery (axillary-
Figure 1. Cancion system for CAFA. The centrifugal flow pump
(a), driven by a magnetic motor (b), draws blood from the percu-
taneously placed inflow cannula (c), positioned in the left iliac
artery, and returns to the descending thoracic aorta via the pig-
tail outflow cannula (d), percutaneously placed via the right fem-
oral artery. Flow is monitored by a flow sensor (e), positioned on
the outflow tubing, and is regulated by the controller (f).
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femoral configuration). In the remaining 19 patients, pump outflow
was via a 60-cm-long, 12F cannula inserted through a percutane-
ously inserted right femoral arterial sheath (femoral-femoral config-
uration). The terminal end-hole pigtail of the cannula was positioned
under fluoroscopy in the thoracic aorta just above the level of the
tracheal carina. The inflow and outflow cannulas were connected via
PVC tubing to a bearingless, magnetically levitated centrifugal pump
(32 mL priming volume) designed to minimize hemolysis and
thrombosis. The blood capacity of the entire system (including the
pump and the intracorporeal portions of the cannulas) is 108 mL.
The pump is activated by a bearingless magnetoelectric motor
connected to a controller. Pump speeds of 2000 to 5400 rpm were
used to achieve flow rates of 1.1 to 1.5 L/min. When the pump is
activated, the flow loop results in superimposition of additional
nonpulsatile flow on pulsatile cardiac output within the descending
aorta between the outflow and inflow cannulas.
In vitro and in vivo safety studies have demonstrated that the
Cancion system produces a minimal or an acceptable degree of
hemolysis (predefined as absence of an increase in plasma free
hemoglobin to 40 mg/dL on 2 consecutive measurements) when
used for up to 5 days. For the duration of circulatory support,
anticoagulation with continuous infusion of unfractionated heparin
was used to maintain activated partial thromboplastin time between
65 and 85 seconds. The system was inserted and removed in a
cardiac catheterization laboratory (femoral-femoral) or an operating
room (axillary-femoral). After insertion, the patient was transferred
to an intensive care unit for the duration of device treatment, for up
to 5 days. After the device was removed, the patient remained in the
intensive care unit for an additional 24 hours of hemodynamic
monitoring.
Measurements
Baseline hemodynamic measurements were performed in duplicate
and were averaged. In the United States, PCWP was recorded at
6-hour intervals beginning 24 hours before device implantation.
Cardiac output was determined by the thermodilution technique.
After device implantation, hemodynamic and laboratory data were
acquired at predefined time intervals during the study and were
continued after device explantation for an additional 24 hours.
Statistical Analysis
Results are expressed as meanSD, unless otherwise specified.
Overall significance for each parameter was tested with linear
regression, testing for a trend over time. The regression considered
patients as random effects; repeated-measures analysis was used
because of potential within-patient correlations. Measurements at
each time point were compared with baseline values with 2-tailed
paired t tests; no adjustment for multiple comparisons has been
performed when reporting these probability values. Two-sided prob-
ability values are reported. Statistical computations were performed
with SAS version 8.2.
Approximately 8% (27/327) of the PCWP values were missing.
For pointwise comparisons against baseline and for the summary
statistics, missing values were imputed with the last observation
carried forward (LOCF) technique; missing values at the 1-hour time
point were imputed to be the mean of the baseline and 2-hour values.
This LOCF method is slightly biased against detecting a trend over
time. The regressions used actual observed data only, although the
same significance is obtained with the LOCF data. A similar
situation prevailed with the other response variables.
Results
Between December 2001 and March 2004, 24 patients (12 in
the United States and 12 in Europe) underwent treatment with
the Cancion system (3 females, 21 males). Baseline charac-
teristics are listed in Table 1. The average age was 54 years,
with a range from 26 to 75 years. Eight patients had ischemic
cardiomyopathy, 14 had idiopathic dilated cardiomyopathy, 1
had valvular heart disease, and 1 had graft arteriosclerosis 39
months after cardiac transplantation.
The Cancion system was implanted for a duration of 2 to
119 hours, with an average of 7733 hours. Pump flows
ranged between 1.07 and 1.56 L/min, with an average of
1.340.12 L/min. One patient (with graft arteriosclerosis)
was in cardiogenic shock with hyperkalemia at the time of
implantation and died 2 hours after the implantation, with
continued cardiogenic shock and progressive hyperkalemia.
Efficacy analysis was performed in the remaining 23 patients.
Medication doses remained stable throughout the treatment
period. The most commonly prescribed intravenous inotropic/
vasodilator agents were dobutamine (n17) and milrinone
(n14). Among patients completing 3 days of treatment,
mean doses of dobutamine and milrinone were 6.33.8 and
5.62.7 g · kg1 · min1 and 0.480.21 and 0.440.25
g · kg1 · min1 at baseline and day 3, respectively. Daily
furosemide doses averaged 134183 and 135128 mg at
baseline and day 3, respectively.
At baseline, PCWP averaged 28.44.9 mm Hg, cardiac
index (CI) averaged 1.940.42 L · min1 · m2, and mean
arterial pressure averaged 76.99.3 mm Hg. Table 2 lists
mean hemodynamic values at baseline and throughout the
first 24 hours after device implantation. Table 3 lists hemo-
dynamic values at baseline and at 8-hour intervals up to 72
hours after device implantation, and then 12 and 24 hours
after device removal, for the 20 patients who received
treatment for at least 48 hours. CAFA treatment resulted in a
reduction in PCWP, pulmonary artery pressure, and systemic
vascular resistance (SVR) and an increase in CI. As shown in
Figure 2, for US patients (in whom measurements were
obtained for 24 hours before device implantation), initiation
of CAFA treatment resulted in an abrupt and progressive
reduction in PCWP relative to a stable baseline over the
preceding 24 hours. Data for all 23 patients are shown in
Figure 3. Improvements in all parameters were sustained and
progressive over 72 hours of treatment. At 12 and 24 hours
after removal of the device, all hemodynamic benefits were
still present. Mean arterial pressure decreased from baseline
during the first several hours of treatment and remained stable
during the remainder of device treatment and after removal.
Figure 4 plots PCWP versus CI at baseline, after 24 and 72
hours of CAFA, and at 24 hours after device removal for the
20 patients who received treatment for at least 48 hours. The
findings are consistent with an improvement (upward shift) in
the Starling curve, which persisted 24 hours after discontin-
uation of treatment.
Weak inverse correlations were observed between the
24-hour change from baseline in both SVR (r0.42;
P0.048) and PCWP (r0.40; P0.056) with baseline CI.
Patients with lower baseline CI tended to show greater
reductions in SVR and PCWP with treatment.
Serum creatinine trended downward from baseline over the
first 48 hours of treatment, with the effect sustained at 72
hours (overall P0.095; Figure 5). In the US patients only,
serum creatinine levels were repeated an average of 3 days
after discontinuation of treatment, and at that time, levels had
increased again from 1.210.35 mg% on treatment day 3 to
1.430.39 mg%.
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Adverse Effects
A total of 8 patients experienced complications during treat-
ment. One death (described above) was not considered related
to the device. The remaining 7 patients had no lasting
sequelae. In 2 patients, the percutaneous device was removed
on the second day because of bleeding from the insertion site.
In both cases, bleeding was controlled by manual compres-
sion after device removal. In 1 patient, during surgical inflow
cannula insertion, there was dissection of the profunda
femoris artery, which was surgically repaired without
sequela. In 1 patient, the right iliac artery was dissected during
sheath exchange after removal of the pigtail cannula. This event
was managed conservatively, without sequela. In 1 patient, the
percutaneous device was removed on the fourth day because of
loss of left pedal pulse, which returned immediately after device
removal. In 2 patients, the device was removed owing to
thrombosis within the cannulas, which resulted in reduced flow.
In both patients, 1 of whom had deficiency of antithrombin III,
anticoagulation was subtherapeutic. Neither patient experienced
any clinical embolic events.
TABLE 1. Baseline Characteristics
Patient Age, y Gender Diagnosis EF, % Medicines
1 64 M Ischemic cardiomyopathy 25 Dobutamine
2 53 M Graft arteriosclerosis 20 Dopamine
3 70 M Dilated cardiomyopathy 8 Dopamine
4 40 M Dilated cardiomyopathy 15 Dobutamine, milrinone
5 51 M Ischemic cardiomyopathy 15 Dobutamine, milrinone
6 67 M Ischemic cardiomyopathy NA Dobutamine, dopamine
7 65 F Valvular heart disease 20 Dobutamine, dopamine
8 60 M Ischemic cardiomyopathy 28 Dobutamine, milrinone
9 52 M Dilated cardiomyopathy 19 Dobutamine
10 51 M Ischemic cardiomyopathy 20 Dobutamine, nitroprusside
11 69 M Ischemic cardiomyopathy 15 Dobutamine
12 52 M Dilated cardiomyopathy 22 Dobutamine
13 51 F Dilated cardiomyopathy 17 Milrinone
14 60 M Ischemic cardiomyopathy 25 Milrinone
15 54 M Dilated cardiomyopathy 22 Milrinone
16 35 M Dilated cardiomyopathy 8 Dobutamine, milrinone
17 46 M Dilated cardiomyopathy 10 Dobutamine
18 49 M Dilated cardiomyopathy 15 Dobutamine, milrinone, nesiritide
19 53 M Ischemic cardiomyopathy 19 Dobutamine, dopamine, milrinone, nesiritide
20 26 M Dilated cardiomyopathy 12 Dobutamine, milrinone
21 75 M Dilated cardiomyopathy 18 Milrinone
22 44 F Dilated cardiomyopathy 24 Dobutamine, milrinone
23 70 M Dilated cardiomyopathy 13 Dobutamine, milrinone
24 49 M Dilated cardiomyopathy 12 Milrinone
NA indicates not available.
TABLE 2. Hemodynamics Over the Initial 24 Hours of Treatment (n23; MeanSD)
Hours After Implantation
Overall
Significance†Baseline 1 2 4 8 12 16 20 24
PCWP, mm Hg 28.44.9 24.87.2* 24.38.6* 24.58.3* 24.38.9 21.88.1* 21.77.2* 21.16.6* 21.88.6* P0.0014
PAP, mm Hg 40.96.1 37.38.8* 38.59.9 38.49.5 37.810.7 34.98.4* 34.58.9* 34.88.7* 34.69.8* P0.0005
CI, L min1 m2 1.940.42 2.060.46 2.090.44 2.120.41 2.130.58 2.170.56* 2.030.45 2.180.55* 2.100.43* NS
HR, bpm 8918 9017 9016 8817 9216 9218 8918 8918 8818 NS
BP, mm Hg 76.99.3 72.410.5* 72.79.9 70.39.2* 69.99.4* 67.38.1* 70.18.9* 68.510.8* 68.712.5* P0.01
SVR, dyne  s  cm5 1454486 1352500 1289508* 1233500* 1230456* 1179429* 1323498 1203478* 1195421* NS
PVR, dyne  s  cm5 276115 262108 265128 278116 302196 272114 284102 283140 267138 NS
BP indicates mean arterial pressure; HR, heart rate; PAP, mean pulmonary artery pressure; and PVR, pulmonary vascular resistance.
*P0.05 vs baseline.
†By repeated-measures linear trend analysis.
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Discussion
Despite substantial advances in medical treatment for heart
failure, hospitalizations for this condition continue to be
common, representing a major source of morbidity and
cost.1 Heart failure exacerbations are characterized by
manifestations of volume overload, low cardiac output, or
both.10,11 Medical treatment, including intravenous diuret-
ics, vasodilators, and inotropic agents, are not uniformly
successful in achieving the desired clinical improvement
and are suspected of contributing to adverse clinical
outcomes.12–18 In the present study of patients with severe
heart failure exacerbation and persistent hemodynamic
derangement despite intravenous diuretic and inotropic
and/or vasodilator therapy, we observed that CAFA, with
the Cancion system, markedly improved PCWP, pulmo-
nary artery pressure, and CI in association with reduced
SVR. Hemodynamic improvement was still present after
discontinuation of flow augmentation. Serum creatinine
trended downward during treatment. This initial human
investigation provides encouraging evidence for a poten-
tially important clinical role for this novel treatment.
Ongoing investigation is directed toward determining a
role for CAFA in facilitating recovery from heart failure
exacerbation refractory to conventional medical treatment.
CAFA differs from all previously applied forms of circu-
latory assistance. With an arterial-to-arterial flow circuit,
drawing blood from the iliac artery and returning it to the
descending thoracic aorta, the Cancion system does not
assume or directly augment cardiac output. Previous devices,
including one that is percutaneously implanted with 15F to
21F cannulas (CardiacAssist, Inc),19 are designed to directly
augment cardiac output, in parallel with the intrinsic circula-
tion. These auxiliary flow systems require high-flow pumps,
large-bore cannulas, and surgical or highly invasive implan-
tation techniques. They are, therefore, reserved for the most
severely ill patients who are, however, candidates for com-
plex, invasive procedures. Although the initial 5 patients
enrolled in the present study had surgically implanted cannu-
las, in the subsequent 19 patients, CAFA was achieved with
a simple percutaneous procedure, performed in the catheter-
ization laboratory. CAFA was provided by a centrifugal
pump that generates up to 1.5 L/min of flow.




Significance†Baseline 8 16 24 32 40 48 56 64 72 x12 x24
PCWP, mmHg 28.54.9 25.88.3 22.86.7* 22.39.0* 23.66.1* 25.07.0* 23.87.6* 22.67.7* 21.86.5* 19.87.0* 19.76.8* 21.26.6* P0.0001
PAP, mmHg 41.36.1 39.99.8 36.18.4* 35.79.6* 34.97.9* 37.48.4* 37.39.7* 37.99.2 35.910.4* 35.29.3* 33.26.1* 36.28.0* P0.0001
CI, L min1 m2 1.970.44 2.100.55 2.030.35 2.090.45 2.080.37 2.230.50* 2.190.51 2.220.52 2.240.50* 2.270.43* 2.370.50* 2.340.54* P0.0013
HR, bpm 8918 9317 8918 9019 9016 8917 9018 9017 9015 9015 9316 9017 NS
BP, mmHg 74.76.6 70.78.9 69.88.2* 67.911.6* 69.26.6* 70.411.2 69.18.3* 66.09.0* 68.79.7* 69.210.9* 67.55.4* 68.48.5* P0.0014
SVR,
dyne  s  cm5
1413453 1224419 1268383 1177382* 1208350 1186412* 1170396* 1086350* 1142386* 1136381* 1051326* 1037292* P0.0008
PVR,
dyne  s  cm5
274114 288142 28492 282138 231104 23673 235106 25092 258109 272107 24266 25678 NS
BP indicates mean arterial pressure; HR, heart rate; PAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; x12, 12 hours after device
removal; and x24, 24 hours after device removal.
*P0.05 vs baseline.
†By repeated-measures linear trend analysis, including all values from baseline through 72 hours.
Figure 2. Effects of CAFA on PCWP
(meanSEM) during the first 24 hours of
treatment in US patients (n12), in
whom serial measurements were made
during the 24 hours preceding device
implantation. Measurements remained
stable before initiation of device treat-
ment, after which PCWP decreased rap-
idly and continued to decrease over the
subsequent 12 hours.
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One potential explanation for hemodynamic improvement
with CAFA relates to cardiac unloading through conservation
of forward flow throughout the cardiac cycle. Additionally,
the early and progressive decrease in SVR suggests that
augmentation of flow within the aorta in patients with
reduced cardiac output stimulates vasodilation within down-
stream resistance arterial beds through flow-mediated vaso-
dilation. Utilizing an in vitro model of the central arterial
circulation, Gharib and Beizaie20 observed that during low-
flow states, the flow pattern is perturbed, with reversal of
blood flow along the aortic borders during diastole. CAFA
favorably alters this pattern by providing antegrade flow
throughout the cardiac cycle. Such changes in arterial flow
patterns are likely to have a major influence on endothelial
release of vasoactive mediators, such as nitric oxide, as has
been demonstrated by Lu and Kassab.21 Our finding in the
present study that the magnitude of the observed decrease in
SVR and in PCWP correlated inversely with baseline CI
(that is, patients with the lowest baseline CI showed the
greatest magnitude of response to CAFA) is consistent with
the hypothesis that a low-flow state within the aorta signals
downstream vasoconstriction, and augmentation of aortic
flow reverses this effect.
In a study by Haithcock et al,6 4 hours of CAFA within a
microembolic, ischemic, chronic myopathic canine model
achieved progressive reduction in left heart filling pressure
associated with reductions in LV volumes and increases in
stroke volume, cardiac output, and EF. There was no discernible
change in heart rate or arterial pressure. Wasler et al7 previously
reported the first human application of this technique in a patient
with ischemic cardiomyopathy who was admitted for exacerba-
tion of heart failure. During 3 days of treatment with CAFA,
there were substantial decreases in PCWP, LV dimensions, and
serum creatinine, with increases in CI and EF.
We enrolled patients with severe exacerbations of chronic
heart failure, characterized by high cardiac filling pressures
Figure 3. Effects of CAFA on PCWP
within the entire patient population. A,
Results (meanSEM) at baseline and
during the first 24 hours of treatment in
23 patients. B, Results at baseline, dur-
ing 72 hours of treatment, and 12 and 24
hours after discontinuation of treatment
(12-P, 24-P) for the 20 patients who
underwent treatment for at least 48
hours. Asterisks denote significant differ-
ence from baseline by t test (P0.05).
Probability values denote overall signifi-
cance by repeated-measures linear trend
analysis applied to all data through 24
(A) or 72 (B) hours. B1 and B2 are dupli-
cate baseline measurements obtained 10
minutes apart.
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and low CI, whose conditions were poorly responsive to
intravenous diuretics and inotropes and/or vasodilators. Our
observations of marked improvement in hemodynamics,
which persisted 24 hours after discontinuation of CAFA,
support a role for this form of treatment as an adjunct to
medical therapy in patients requiring hospitalization because
of worsening heart failure. An increase in CI (excluding
augmented aortic flow), at a time when PCWP is markedly
reduced from baseline, indicates that the LV has moved to a
more favorable Starling curve. CAFA treatment is likely to
break a vicious circle characterized by reduced aortic flow,
worsening peripheral vasoconstriction, increasing filling
pressure, and further reduction in cardiac output, providing an
opportunity for sustained clinical benefit. Furthermore, a
prolonged reduction in filling pressures and SVR, with a
reduction in LV volumes (and presumed reduction in wall
stress) as observed in animal investigations, may achieve
recovery in myocardial function.
The downward trend in serum creatinine also favors
clinical usefulness for this technique. There has been substan-
tial recent attention given to the “cardio-renal syndrome” of
severe heart failure, with growing evidence that worsening
renal function during hospitalization carries a poor progno-
sis.22–25 It is possible that CAFA directly augments renal
blood flow, or alternatively, that the same signals responsible
for downstream vasodilation (eg, nitric oxide) favorably
affect glomerular and/or tubular function. Ongoing animal
investigations are directed toward further exploration of the
mechanisms of CAFA action on central hemodynamics, as
well as on renal hemodynamics and glomerular and tubular
function.
Observations in the present study justify investigations of
the potential for translating the hemodynamic and renal
benefits of CAFA treatment into improved symptoms and
clinical outcomes. The ongoing Multi-center Trial of the
Orqis Medical Cancion System for the Enhanced Treatment
Figure 4. Plot of PCWP vs CI
(meanSEM) at baseline (B), after 24
and 72 hours of CAFA (24 and 72,
respectively), and 24 hours after discon-
tinuation of treatment (24P) in the 20
patients who underwent treatment for at
least 48 hours. The concomitant reduc-
tion in PCWP and increase in CI defines
an upward shift in the LV Starling curve.
Figure 5. Serum creatinine values
(meanSEM) at baseline and during
CAFA. Overall P0.095 by repeated-
measures linear trend analysis.
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of Heart Failure Unresponsive to Medical Therapy
(MOMENTUM) is a randomized, controlled trial of the
effects of CAFA therapy added to medical therapy versus
medical therapy alone on both hemodynamics and clinical
outcomes.
In summary, CAFA therapy with the Orqis Cancion system
achieved significant improvement in hemodynamics that
were still present after termination of treatment in patients
hospitalized with an exacerbation of chronic heart failure that
had been inadequately responsive to medical therapy, includ-
ing intravenous diuretics and inotropes and/or vasodilators.
These benefits were most pronounced in patients with lower
baseline cardiac indices and were accompanied by beneficial
trends in serum creatinine. Although the precise mechanism
for CAFA benefit continues to be explored, it is possible that
effects derive, at least in part, from modulation of signals
emanating from the aorta responsible for downstream vascu-
lar effects. An ongoing investigation is exploring a potential
role of nitric oxide in mediating such effects. CAFA,
achieved through a readily implanted percutaneous device,
represents a promising mode of therapy for patients with
severe heart failure. The clinical impact of this mode of
therapy is currently under investigation.
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